Physician profile
Dana M Baker
NPI 1205354453
$8,448.30
in general payments reported to CMS, 2019-2025
32 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $169 · 2022: $2,031 · 2023: $2,244 · 2024: $2,147 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,158 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,158.06 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $968.44 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $932.50 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $916.19 | 2022-2025 | |
| Alkermes, INC. | $894.06 | 2022-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $863.55 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $676.39 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $613.89 | 2021-2025 | Caplyta |
| Novo Nordisk INC | $404.80 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Neurocrine Biosciences, INC. | $351.28 | 2022-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $229.26 | 2022-2024 | Spravato, Invega, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $216.87 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $163.62 | 2024-2025 | Cobenfy |
| Lilly USA, LLC | $160.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Vanda Pharmaceuticals INC. | $147.41 | 2024-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $132.94 | 2022-2025 | Aplenzin, Wellbutrin |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $103.95 | 2024 | Veozah |
| Avanir Pharmaceuticals, INC. | $91.97 | 2021-2022 | |
| Exact Sciences Corporation | $74.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $66.42 | 2023-2024 | Quviviq |
| Collegium Pharmaceutical, INC. | $65.94 | 2025 | Jornay Pm |
| Pfizer INC. | $64.17 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $59.71 | 2022-2024 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $50.75 | 2022 | |
| Indivior INC. | $47.07 | 2025 | Sublocade |
| Jazz Pharmaceuticals INC. | $32.39 | 2021-2022 | |
| Tris Pharma INC | $30.89 | 2022 | |
| Braeburn INC. | $18.90 | 2024 | Brixadi |
| Biohaven Pharmaceutical Holding Company LTD. | $18.56 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2023 | |
| Abbott Laboratories | $12.64 | 2022 | |
| Eisai INC. | $12.10 | 2021 | |
| Corium, LLC | $10.21 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.